Autres langues Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Produits pharmaceutiques

Marché Fermé - Japan Exchange 08:30:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
5 969,00 ^JPY	+1,43%		+0,02%	+23,45%

23/09	Double actualité pour Roche
23/09	Roche propose l’ancien PDG de Takeda au conseil d’administration	RE

Autres langues

23/09	Two announcments for Roche
23/09	Aktien Schweiz Vorbörse: SMI freundlich erwartet - Nahosthoffnungen und Ölpreis
23/09	Roche proposes former Takeda CEO for board seat
23/09	Roche schlägt Christophe Weber zur Wahl in den Verwaltungsrat vor
22/09	Takeda Pharmaceutical Company Limited Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research Led by Phase 3 Arcotatug Tavatecan Data At Esmo 2026
22/09	Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
21/09	Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on
21/09	Pharma sector doubles down on AI to slash costs, timelines
21/09	Takeda Announces Appointment of Enrique Vázquez as Head of Public Affairs in Spain
18/09	Dr. Reddy's, Takeda Sign Deal to Distribute QDENGA Dengue Vaccine in India
18/09	Dr. Reddy's Enters Agreement to Bring Takeda's Dengue Vaccine to India
18/09	Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
18/09	Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine
16/09	Pharma sector doubles down on AI to slash costs, timelines
14/09	Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading
14/09	U.S. FDA Grants Priority Review to Takeda Pharmaceutical's Zasocitinib NDA for Plaque Psoriasis
14/09	Takeda's Investigational Plaque Psoriasis Drug Accepted for Priority Review by US FDA
14/09	Takeda Pharmaceutical Company Limited Receives U.S. FDA Acceptance Of New Drug Application Under Priority Review For Zasocitinib In Moderate-To-Severe Plaque Psoriasis
14/09	U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
10/09	Takeda Pharmaceutical : Announces Planned Retirement of President of Research & Development Andy Plump
09/09	Takeda Publishes Phase 3 Data Demonstrating Oveporexton Improves Narcolepsy Type 1 Symptoms
09/09	New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
08/09	Pharvaris' genetic disorder drug meets main goal in late-stage trial
04/09	After obesity, pharma seeks its next mega-blockbuster in sleep
04/09	Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing